ArticleInfection and immunity2001
In vitro and in vivo neutralization of the relapsing fever agent Borrelia hermsii with serotype-specific immunoglobulin M antibodies.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Antigenic variation is caused by long plasmid segment conversion in a hard tick-borne relapsing fever Borrelia miyamotoi.PLoS pathogens · 2025Article
- Borrelia burgdorferi Infection-Induced Persistent IgM Secretion Controls Bacteremia, but Not Bacterial Dissemination or Tissue Burden.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Article
- Identification of theProceedings of the National Academy of Sciences of the United States of America · 2022Article
- The First Immunocompetent Mouse Model of Strictly Human Pathogen, Borrelia recurrentis.Infection and immunity · 2021Article
- Pathogenesis of Relapsing Fever.Current issues in molecular biology · 2021Review
- Immunological Responses to the Relapsing Fever SpirocheteInfection and immunity · 2019Article
- Host Immune Evasion by Lyme and Relapsing Fever Borreliae: Findings to Lead Future Studies forFrontiers in immunology · 2017Review
- Pathogen and Host Response Dynamics in a Mouse Model of Borrelia hermsii Relapsing Fever.Veterinary sciences · 2016Article
- Variable Major Proteins as Targets for Specific Antibodies against Borrelia miyamotoi.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Antigenic Variation in Bacterial Pathogens.Microbiology spectrum · 2016Article
- Expression of the Tick-Associated Vtp Protein of Borrelia hermsii in a Murine Model of Relapsing Fever.PloS one · 2016Article
- Article
- Vaccination with the variable tick protein of the relapsing fever spirochete Borrelia hermsii protects mice from infection by tick-bite.Parasites & vectors · 2015Article
- Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens.Ticks and tick-borne diseases · 2015Article
- Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.Infection and immunity · 2014Article
- Fibronectin-binding protein of Borrelia hermsii expressed in the blood of mice with relapsing fever.Infection and immunity · 2014Article
- Inactivation of genes for antigenic variation in the relapsing fever spirochete Borrelia hermsii reduces infectivity in mice and transmission by ticks.PLoS pathogens · 2014Article
- Efficient B cell responses to Borrelia hermsii infection depend on BAFF and BAFFR but not TACI.Infection and immunity · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The antigenic variation of the relapsing fever agent Borrelia hermsii is associated with changes in the expression of the Vlp and Vsp outer membrane lipoproteins. To investigate whether these serotype-defining proteins are the target of a neutralizing and protective antibody response, monoclonal antibodies were produced from spleens of infected mice just after clearance of serotype 7 cells from the blood. Two immunoglobulin M monoclonal antibodies, H7-7 and H7-12, were studied in detail. Both antibodies specifically agglutinated serotype 7 cells and inhibited their growth in vitro. Administered to mice before or after infection, both antibodies provided protection against infection or substantially reduced the number of spirochetes in the blood of mice after infection. Whereas antibody H7-12 bound to Vlp7 in Western blotting, enzyme-linked immunosorbent assay, and immunoprecipitation assays, as well as to whole cells in other immunoassays, antibody H7-7 only bound to wet, intact cells of serotype 7. Antibody H7-7 selected against cells expressing Vlp7 in vitro and in vivo, an indication that Vlp7 was a conformation-sensitive antigen for the antibody. Vaccination of mice with recombinant Vlp7 with adjuvant elicited antibodies that bound to fixed whole cells of serotype 7 and to Vlp7 in Western blots, but these antibodies did not inhibit the growth of serotype 7 in vitro and did not provide protection against an infectious challenge with serotype 7. The study established that a Vlp protein was the target of a neutralizing antibody response, and it also indicated that the conformation and/or the native topology of Vlp were important for eliciting that immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.